Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH-Treg: Treg/Tcon Adoptive Immunotherapy in High-Risk AML
NCT07552649Phase 2Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Treg/Tcon adoptive immunotherapy in acute myeloid leukemia (AML). Primary endpoint: Disease-Free Survival at 2 years. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Treg/Tcon adoptive immunotherapy
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07552649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552649.